{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-209296","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2024-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.101064+00:00","generated_at":"2026-05-31T07:05:14.737988+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Delcath Systems Announces Positive Independent Study Results for Liver-Directed Therapy in Uveal Melanoma","bullets":["Study of 167 patients showed median melanoma-specific survival of 28 months with first-line liver-directed therapy vs 10 months with systemic therapy.","Patients diagnosed 2016-2021 receiving liver-directed therapy had median MSS of 30 months, compared to 20 months for 2005-2015 cohort.","CHEMOSAT Hepatic Delivery System was used in the study; 30 of 56 patients in 2016-2021 period received CHEMOSAT.","Study published in Therapeutic Advances in Medical Oncology, conducted by University of Tübingen researchers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-209296","json":"https://secwatch.observer/filing/0001193125-24-209296.json","markdown":"https://secwatch.observer/filing/0001193125-24-209296.md","text":"https://secwatch.observer/filing/0001193125-24-209296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000119312524209296/0001193125-24-209296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000119312524209296/d848222d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:05:14.737988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}